基于MRI的影像组学方法改进乳腺癌组织学分级
结果显示RG2-high复发风险显著高于RG2-low(HR 2.20),且在ER+和ER+LN-亚组中验证。
要点
- Rad-Grade可将NHG 2乳腺癌再分层为RG2-low和RG2-high,提示不同侵袭性。
- RG2-high较RG2-low复发风险增加(HR 2.20),独立于既定风险因素。
- 该影像组学标签有望作为基因表达谱的替代方法辅助治疗决策。
核心结论
- 基于MRI的影像组学再分层为NHG 2肿瘤提供了一种成本有效的基因表达谱替代方案,可能改善临床决策。
研究设计与样本
- 使用LASSO逻辑回归算法基于MRI图像特征构建预测组织学分级的影像组学标签。
临床应用与阅片要点
- 日常阅片可关注MRI影像组学特征,辅助NHG 2乳腺癌的风险再分层。
- 报告时可提示RG2-high亚型复发风险较高,需结合临床风险因素综合评估。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 单中心数据,外部泛化性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Nottingham histological grade (NHG) 2 breast cancer has an intermediate risk of recurrence, which is not informative for therapeutic decision-making. We sought to develop and independently validate an MRI-based radiomics signature (Rad-Grade) to improve prognostic re-stratification of NHG 2 tumors.
MATERIALS AND METHODS: Nine hundred-eight subjects with invasive breast cancer and preoperative MRI scans were retrospectively obtained. The NHG 1 and 3 tumors were randomly split into training and independent test cohort, with the NHG 2 as the prognostic validation set. From MRI image features, a radiomics-based signature predictive of the histological grade was built by use of the LASSO logistic regression algorithm. The model was developed for identifying NHG 1 and 3 radiological patterns, followed with re-stratification of NHG 2 tumors into Rad-Grade (RG)2-low (NHG 1-like) and RG2-high (NHG 3-like) subtypes using the learned patterns, and the prognostic value was assessed in terms of recurrence-free survival (RFS).
RESULTS: The Rad-Grade showed independent prognostic value for re-stratification of NHG 2 tumors, where RG2-high had an increased risk for recurrence (HR 2.20, 1.10-4.40, p = 0.026) compared with RG2-low after adjusting for established risk factors. RG2-low shared similar phenotypic characteristics and RFS outcomes with NHG 1, and RG2-high with NHG 3, revealing that the model captures radiomic features in NHG 2 that are associated with different aggressiveness. The prognostic value of Rad-Grade was further validated in the NHG2 ER+ (HR 2.53, 1.13-5.56, p = 0.023) and NHG 2 ER+LN- (HR 5.72, 1.24-26.44, p = 0.025) subgroups, and in specific treatment contexts.
CONCLUSION: The radiomics-based re-stratification of NHG 2 tumors offers a cost-effective promising alternative to gene expression profiling for tumor grading and thus may improve clinical decisions.
引用
- Jiang, Li, Luo, et al. An MRI-based Radiomics Approach to Improve Breast Cancer Histological Grading. Acad Radiol. 2023. PMID: 36609032. doi:10.1016/j.acra.2022.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。